PROGRESSIVE tumour growth in humans and laboratory animals is frequently coincident with progressive immunosuppression. Tumour-specific immune responses which develop during early tumour growth decline and often disappear entirely (Deckers et al., 1973; Howell, Esber and Law, 1974; Youn, LeFrancois and Barski, 1973; Whitney, Levy and Smith, 1974) . General immune responses, such as delayed hypersensitivity reactions to recall antigens and in vitro lymphocyte stimulation by mitogens and antigens, are also depressed in many cancer patients (Krant et al., 1968; Golub, O'Connell and Morton, 1974) . Similarly, the response of mouse spleen cells to both mitogens and specific antigens declines with increasing tumour size (Adler, Takiguchi and Smith, 1971; Rowland et al., 1973) . At present many immunological functions have been suggested to be involved in tumour growth.
Recent theories have suggested that tumours grow progressively because of the presence of blocking factors, particularly blocking antibodies or antigen-antibody complexes (Baldwin, Price and Robins, 1973; Hellstr6m and Hellstrom, 1970; Gorczynski et al., 1974) ; because of a defect in the host's immune response, both cellular and humoral; or because of suppressor elements that develop concurrently with tumour growth and actively antagonize the host's response to tumours and other antigens (Kirchner et al., 1974;  Whitney Waldmann and Broder, 1977) .
Numerous time-course experiments describing the development of cellmediated immunity in tumour-bearing hosts have shown that an "eclipse" of tumour-specific immunity occurs after the tumour reaches a certain critical size. In all cases, restoration of an immuno-logically responsive state followed surgical removal of the tumour (LeFrancois et al., 1971; Heppner, 1972) . Other work has shown that non-specifically depressed cellmediated immunity in tumour-bearing hosts could be restored to normal levels after surgical resection (Gillette and Boone, 1975; Adler et al., 1971) . Loss of serumblocking activity in tumour-bearing hosts following surgical removal of the tumour has also been well documented (Bray and Keast, 1975; Bray and Holt, 1975) .
Previous studies in our laboratory have shown that the decrease in lymphocyte competence that occurs with progressive tumour growth was concomitant with the appearance of an immuno-suppressive serum factor which inhibited lymphocyte proliferation. This suppressive factor separated with the 7S immunoglobulins on Sephadex G150 and G-200, and could be removed by absorption on anti-mouse-Ig columns (Whitney and Levy, 1975; Levy et al., 1976) . It was also shown that mice with tumours developed suppressor cells in their spleens which inhibited mitogen responses of normal lymphocytes just as the serum factor did. Treatment of the suppressor spleen population with anti-0 or anti-Ig and complement did not remove the suppressor cells. In contrast, treatments which remove adherent cells, including passage through nylon wool columns and treatment with carbonyl iron, effectively removed the suppressor activity. It was concluded that the suppressor cell was of the macrophage/ monocyte series (Pope et at., 1976) .
The present study was undertaken to follow the restoration of normal lymphocyte function after resection of solid tumours from DBA/2J mice. Recovery of normal function was correlated with the disappearance of the suppressive serum factor and splenic suppressor cells.
MATERIALS AND METHODS

Experimental animals
DBA/2J female mice (Jackson Laboratory, Bar Harbor, Maine) aged 8-10 weeks were used in all experiments.
Tumour
The tumour used was a methycholanthreneinduced rhabdomyosarcoma (M-1) obtained originally from the Jackson Laboratory, and maintained both in vivo and in vitro in this laboratory for the past 4 years. Methods for the maintenance and culture of the tumour have been described elsewhere . Animals were injected with 2 x 104 viable M-1 cells and palpable tumours were observed 7-10 days later. Once palpable, the tumours grew uniformly. The tumour was grown s.c. on the animal's right abdominal side, thus allowing easy surgical resection.
Surgical resection
Resections were carried out 32 days after tumour implantation. At this time, the tumour mass was 3-5-4-5 g. . The mitogen concanavalin A (conA) was used at a final concentration of 4 ,ug/ml. When testing for competence, the various cell populations were tested separately at 5 x 105 cells/well. When .
In vitro antibody production Spleen cells from normal and tumourresected mice were cultured at 106 and 2 x 106 per microtitre plate containing 0-25 ml RPMI-1640 medium supplemented with 10% FCS (Flow Laboratories, Lot No. 40551044) and 5 x 10-5 M 2-mercaptoethanol. Antigens used were either 2-5 x 106 SRBC/ml or 0-1 jug/ml DNP-LPS, the latter of which behaves in vitro as a T-cell-independent antigen. The DNP-LPS was prepared according to Jacobs and Morrison (1975) . Cultures were incubated at 37°C on a rocking platform. The DNP-LPS cultures were incubated for 3 days and the SRBC cultures for 4 days, as preliminary assays had shown these to be the optimal times for detection of plaque-forming cells (PFC). The number of direct PFC was determined with a microscope-slide assay described previously (Cunningham and Szenberg, 1968) . DNP plaques were determined using SRBC coated with dinitrophenylated rabbit anti-SRBC-Fab' (Strausbauch, Sulica and Givol, 1970 Levy, , 1975 
RESULTS
Immune competence of tumour-resected animals
The general immunological status of normal and tumour-resected animal's spleen cells was determined at various times after surgical resection. In vitro stimulation with conA was used to assess T-cell competence while in vitro antibody production to SRBC and DNP-LPS was used as a measure of B-cell competence. the response. An example of this is clearly shown in Fig. 1 , where during the first 4 days after resection, the addition of 106 tumour-resected animal's spleen cells to 106 normal spleen cells lowered the PFC response to SRBC below that of 106 normal spleen cells alone.
Inhibitory effects of fractionated sera from tumour-resected animals Serum from normal and tumour-resected mice was fractionated on Sephadex G-150, and the Ig-cointaining fraction was tested for its inhibitory activity by adding it to cultures of normal mouse spleen cells stimulated with conA. All serum samples were tested at 200 jtg protein/ml.
The data are shown in Table V . As has been previously noted , serum fraction 1 from normal mice was also somewhat inhibitory. We have shown previously that the spleens of mice bearing large M-1 tumours contained non-specific suppressor cells which could suppress both B-and T-cellmitogen responses of normal syngeneic lymphocytes (Pope et al., 1976) . In these studies, the presence of these cells in animals after resection was assessed both by the mitogen assay previously described and by their ability to suppress both T-cell-dependent and T-cell-independent B-cell responses of normal syngeneic splenocytes in vitro. This assay involved mixing 106 normal spleen cells with 106 spleen cells from resected animals before incubation with antigen. These were run concurrently with cultures of normal splenocytes at 106 and 2 x 106/well. Cultures containing 2 x 106 cells invariably produced higher numbers of PFC. However, suppression is measured by comparing the number of PFC in cultures of 106 normal cells with cultures of 106 normal plus 106 resected-animal's cells. The assumption is made that the resected-animal's cells are non-responsive and therefore contribute nothing. This is a very conservative method for assessing suppression, but we decided that this was preferable to applying a formula to predict theoretical numbers of plaques in the mixed cultures. Using this conservative assay, it can be seen that significant suppression of the anti-SRBC response was 
